200670

Humedix is a biotechnology company that develops and manufactures healthcare products based on biocompatible hyaluronic acid and PDRN technologies. The company operates through two main segments: an aesthetic division and a contract manufacturing organization (CMO) division. Its aesthetic portfolio includes hyaluronic acid fillers such as Elravie Premier and Revoline, botulinum toxin products like Rize Tox, dermal cosmetics under the Elravie brand, and medical devices including DermaShine and DermaAcne. In the CMO segment, Humedix produces specialized pharmaceuticals, arthritis treatments such as Hihyalonce, High Hyal Plus, and High Hyal, ophthalmic solutions like Prosan eye drops, and active pharmaceutical ingredients including hyaluronic acid, PDRN, and heparin sodium. The company supplies domestic and global healthcare markets, with products exported to regions including China, Europe, Southeast Asia, South America, and the Middle East. Humedix has established partnerships for joint research and development with companies such as HLB Pharma, Genen Bio, G2G Bio, Exostemtech, and Epibiotec, focusing on areas like obesity treatment, bio-dressing, and long-acting injectables.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage humedix.com
Sector Healthcare IR page —
Tags
hyaluronic acid, dermal fillers, botulinum toxin, arthritis treatment, ophthalmic solutions, active pharmaceutical ingredients, dermocosmetics, contract manufacturing, pdrn, biocompatible polymers, Elravie Premier, Revoline, Rize Tox, Elravie Cosmetic, DermaShine, DermaAcne, Humedex Dexamethasone Phosphate Sodium Injection, Humedex Lincomycin Hydrochloride Injection, Revitalex Injection, Hudaxin Injection, Eripotin Prefilled Injection, Hihyalonce Injection, High Hyal Plus Injection, High Hyal Injection, Prosan Eye Drops, Prosan 0.3% Eye Drops, High Eye Injection, Heparin Sodium, Elravie Deep Line, Elravie Deep Line-L, Revoline Hara-L, Elravie Premier Soft, Valpian, Humiya Injection, Kirielle, Derma Atom, Elravie Rituo, Red Booster, Olipit Injection
Press page —

Metrics

Valuation  
Market cap ₩ 390.802B
Market cap (USD) $ 287.623M
P/E 8.01
PEG 0.23
P/BV 1.27
P/S 2.20
P/OCF 10.04
P/FCF 15.11
Dividend yield —
Turnover / mcap —
Returns  
ROE 19.6%
ROI 17.3%
ROIC 11.5%
Profit margin 30.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 34.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 52.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 170.053B 161.873B 152.274B 123.173B 110.992B 98.481B 78.619B 64.832B 54.727B 47.134B 42.133B 29.182B 23.544B
Net profit 51.786B 39.259B 24.821B 21.154B 10.051B 15.084B 10.42B 9.208B 11.548B 10.275B 11.623B 6.642B 9.137B
Free cash flow 37.21B 42.146B 21.882B 30.872B 5.441B 6.07B 4.477B 10.821B -10.634B -14.753B 1.034B 6.055B 4.362B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 71.3K 46.15K — — — — — — — — — — —
Price performance 12m 0.54 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 16.7B 17.6B 14.3B 24B 20.7B 22.2B 21.2B 19.7B 20.5B 29.3B
↳ YoY growth +50.6% +5.3% -18.6% +67.0% -13.7% +7.2% -4.3% -7.3% +4.1% +42.9%
↳ 5y CAGR +25.3% +26.7% +13.2% +5.8% +3.8% +6.5% -3.1% +7.2%
Other receivables (KRW) — — — — — — — 925M 2.42B 2.66B
Borrowings, current (KRW) 1.38B — — — — — — — — —
Borrowings, non-current (KRW) 9.22B — — — — — — — — —
Lease liabilities (KRW) — — — — — — — 2.7B 2.96B 1.36B
Cash and deposits (KRW) 59.8B 38B 29.9B 19.1B 28.7B 9.35B 90.7B 80.2B 110B 39.9B
Intangible assets (KRW) 855M 881M 862M 4.16B 6.95B 3.18B 3.05B 2.58B 2.37B 2.35B
Right-of-use assets (KRW) — — — — — — — 2.65B 2.86B 1.3B
Net debt (borrowings + leases - cash) (KRW) -49.2B — — — — — — — — —
Cash flow detail
Operating cash flow (KRW) 7.61B 8.77B 23.8B 13.8B 23.8B 19.2B 38.1B 30.9B 50.7B 45.1B
Purchases of property, plant and equipment (KRW) -22.4B -19.4B -13B -9.33B -17.7B -13.7B -7.23B -9B -8.6B -7.94B
Purchases of intangible assets (KRW) -36.8M -97.9M -177M -8.38M 0.00 -1B 0.00 -26.6M -66.8M -76M
Dividends paid (cash effect) (KRW) -2.6B -4.29B -5.16B -5.34B -4.76B -3.76B -3.76B -7.08B -5.95B -10.8B
Share buybacks (cash effect) (KRW) -2.98B -4.88B -5.15B -151M -2.99B -7M -5.98B 0.00 -3B -5B
Interest paid (cash effect) (KRW) -47.1M — — — — — — -350M — -59.5M
Income taxes paid (cash effect) (KRW) -3.67B -2.97B -1.7B -1.22B -2.17B -1.02B -2.36B -12.7B -5.07B -9.43B
Free cash flow (OCF - PPE - intangibles) (KRW) -14.8B -10.7B 10.6B 4.47B 6.07B 4.44B 30.9B 21.9B 42.1B 37.1B
Income detail
Total comprehensive income (KRW) 10.8B 14B 10.8B 12.1B 17.2B 10.1B 21.2B 24.8B 39.3B 51.8B
Comprehensive income to owners (KRW) 10.6B 12.1B 9.21B 10.4B 15.1B — — — — —
Reported Mar 30, 2018 Mar 30, 2018 Apr 1, 2019 Mar 27, 2020 Mar 11, 2021 Mar 20, 2024 Mar 20, 2024 Mar 20, 2026 Mar 20, 2026 Mar 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 0 Bear 0 Results
현금ㆍ현물배당결정 (분기배당) Bull 2 Bear 0 Capital return

Prompts

Humedix (ticker 200670), listed in South Korea.

ETFs Holding Humedix

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 445 $ 7,357.55 Nov 16, 2026
DFSE 0.01% 1,780 $ 30.036K Nov 12, 2026
DFEV 0.00% 3,028 $ 51.094K Nov 12, 2026
DFEM 0.00% 9,239 $ 155.899K Nov 12, 2026
DFAE 0.00% 6,157 $ 103.893K Nov 12, 2026
DFAX 0.00% 4,989 $ 84.184K Nov 12, 2026
AVEM 0.00% 14,503 $ 239.79K Nov 16, 2026
AVSE 0.00% 72 $ 1,190.43 Nov 16, 2026
AVXC 0.00% 437 $ 7,225.28 Nov 16, 2026